BioSpace News Archive

At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-characterised Safety Over Four Years

Orphan Biovitrum AB (publ) (Sobi™) and Bioverativ Inc., a Sanofi-company, today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in haemophilia.

December 2, 2018
·
12 min read
Biotech Beach

Studies Offer Glimpses into the Future of Medicine

Significant advances in personalized medicine, predictive analytics, and use of big data

December 2, 2018
·
12 min read
Drug Development

IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton’s Tyrosine Kinase Inhibitor to Date

With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients

December 2, 2018
·
15 min read
Drug Development

Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting

-Data Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma-

December 2, 2018
·
18 min read
Drug Development

Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma

39 Percent of Patients in Ongoing Response Two Years after a Single Infusion of Yescarta in the ZUMA-1 Study; Median Overall Survival was Not Reached

December 2, 2018
·
11 min read
Business

NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting

More than One-Third of Drug-Resistant Epilepsy Patients Achieved ≥90% Seizure Reduction with the RNS System

December 2, 2018
·
4 min read
Pharm Country

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting

26-week data from the ongoing 52-week REFLECTIONS B328-06 study met its primary endpoint, demonstrating comparable safety and efficacy for patients with indolent follicular lymphoma

December 2, 2018
·
7 min read
Business

Record-breaking $11.2 million raised for St. Jude Children’s Research Hospital® at 17th annual St. Jude Memphis Marathon® Weekend

In its biggest year yet, St. Jude Memphis Marathon® Weekend presented by Juice Plus+® raised a record $11.2 million for kids at St. Jude Children’s Research Hospital®.

December 2, 2018
·
4 min read
Drug Development

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo

December 2, 2018
·
18 min read
Drug Development

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

Magenta Therapeutics today announced that the Company presented preclinical research on its targeted conditioning programs at the 60th annual meeting of the American Society of Hematology (ASH).

December 2, 2018
·
9 min read